As of November 4, 2026, Aspire Biopharma Holdings, Inc. is a publicly traded company (Nasdaq: ASBP); its largest reported holder is Lance Friedman, with 7.92% on Schedule 13G/A of August 6, 2026, then Gary Shirinyan (7.7%). The largest insider holding is Donald G. Fell, a director, with 20,000 shares (1.4% of shares outstanding), per Form 4/A of June 10, 2025 (Schedule 13G/A, August 6, 2026).
Is this your company?
About to sign with, pay or invest in Aspire Biopharma Holdings, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Aspire Biopharma Holdings, Inc. a real, registered company?
- Aspire Biopharma Holdings, Inc. files with the SEC under CIK 1847345 (its SEC filings).
- Its shares are listed under the ticker ASBP on Nasdaq (also ASBPW) (SEC company record).
- Incorporated in E9; business address in Estero, Florida, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Aspire Biopharma Holdings, Inc. in our court records and SEC 8-K records (as of 2026-11-04).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Gary Shirinyan (filed 2026-08-10).
Who are Aspire Biopharma Holdings, Inc.'s owners and officers?
Aspire Biopharma Holdings, Inc.: business address in Estero, Florida; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-14).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Highbridge Capital Management, LLC | 0% |
| Schedule 13G, 2026-08-10 | Gary Shirinyan | 7.7% |
| Schedule 13G/A, 2026-08-06 | Lance Friedman | 7.92% |
| Schedule 13G, 2026-07-02 | Rubenbauer Alois Ryan Iii | 5% |
| Schedule 13G, 2026-05-15 | Highbridge Capital Management, LLC | 5.2% |
| Schedule 13G/A, 2026-05-13 | Ardsley Advisory Partners LP | 0% |
| Schedule 13G, 2026-02-12 | Ardsley Advisory Partners LP | 7.76% |
Questions about who owns Aspire Biopharma Holdings, Inc.
Who owns Aspire Biopharma Holdings, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Aspire Biopharma Holdings, Inc.: Lance Friedman (7.92%, Schedule 13G/A, filed 2026-08-06), Gary Shirinyan (7.7%, Schedule 13G, filed 2026-08-10) and Rubenbauer Alois Ryan Iii (5%, Schedule 13G, filed 2026-07-02).
Who are the largest shareholders of Aspire Biopharma Holdings, Inc.?
By the share each holder's latest filing reports, the largest holders of Aspire Biopharma Holdings, Inc. on this page are Lance Friedman (7.92%), Gary Shirinyan (7.7%) and Rubenbauer Alois Ryan Iii (5%).
When did Lance Friedman buy into Aspire Biopharma Holdings, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Lance Friedman on this page is the Schedule 13G/A, filed 2026-08-06, reporting 7.92%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Aspire Biopharma Holdings, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Aspire Biopharma Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Aspire Biopharma Holdings, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Aspire Biopharma Holdings, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 20,000 shares (1.4% of shares outstanding) (Form 4/A, 2025-06-10).
Shares outstanding: 1,402,557 as of 2026-08-07, from the company's latest SEC cover page.
How much has Aspire Biopharma Holdings, Inc. raised?
Latest IPO step: Aspire Biopharma Holdings, Inc. amended its IPO registration (S-1/A, 2026-04-10).
IPO filings: S-1/A, 2026-04-10, S-1, 2026-02-17, S-1, 2025-12-03, S-1/A, 2025-09-26, S-1, 2025-09-18.
Keep reading
More on Aspire Biopharma Holdings, Inc. and the records around it.
Aspire Biopharma Holdings, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
Companies that share a holder
- Highbridge Capital Management, LLC also filed stake reports on 83 other companies: Aeon Acquisition I Corp. (Aug 2026), Alpex Acquisition Corp (Aug 2026), Aperture AC (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/aspire-biopharma